Silicon Valley Snake Oil Salesman Gets 8 Years for COVID & Investor Fraud

Silicon Valley isn’t just about innovation; it’s a breeding ground for brazen hustlers. Mark Schena, the former president of medical tech firm Arrayit Corporation, learned that the hard way this week, slapped with an eight-year federal prison sentence and a $24 million restitution order. The feds finally caught up to Schena after years of lies, deceit, and exploiting both investors and a nation desperate for answers during the height of the COVID-19 pandemic.

Schena wasn’t selling a better mousetrap; he was peddling fantasy. Prosecutors proved Schena falsely claimed to have invented a revolutionary disease-testing technology – a claim that formed the cornerstone of a massive investor fraud. He didn’t just exaggerate; he fabricated, luring in unsuspecting investors with promises of a breakthrough that never existed. This wasn’t a case of optimistic marketing; it was a calculated scheme to inflate Arrayit’s value and line Schena’s pockets. The scale of the deception allowed Schena to secure substantial funding, all built on a foundation of lies.

But the investor fraud was only one part of the grift. Arrayit, under Schena’s direction, engaged in widespread health care fraud, specifically through the unnecessary administration of allergy tests. These weren’t legitimate medical procedures; they were a blatant attempt to bill insurance companies for services that provided no benefit to patients. The company actively sought out customers, not to improve their health, but to generate fraudulent revenue. To further amplify the scheme, Arrayit paid illegal kickbacks to marketers, incentivizing them to push these useless tests, creating a network of complicity fueled by greed.

Then came COVID-19. As the world scrambled for testing solutions in early 2020, Schena saw a golden opportunity. He falsely announced that Arrayit had developed a reliable COVID-19 test, even though the company lacked the capacity and the technology to deliver. This was a particularly egregious act, preying on public fear and desperation during a national crisis. The company launched a deceptive marketing campaign, attempting to capitalize on the urgent need for testing, and actively soliciting investments based on a product that was, at best, unreliable and, at worst, completely fictitious.

The sentencing comes after a lengthy investigation led by federal prosecutors, with critical support from the FBI and the Department of Health and Human Services Office of Inspector General (HHS-OIG). The FBI’s investigation delved into Arrayit’s finances, marketing materials, and internal communications, uncovering a pattern of deliberate misrepresentation. HHS-OIG, meanwhile, focused on the healthcare fraud aspect, tracing the fraudulent billing practices and identifying the kickback scheme. The combined effort painted a damning picture of Schena’s deliberate and calculated fraud.

Federal sentencing guidelines for these types of offenses are complex, factoring in the amount of financial loss, the defendant’s criminal history, and the severity of the fraud. The $24 million restitution order reflects the substantial financial harm inflicted upon investors and insurance companies. While eight years is a significant sentence, it’s a stark reminder that white-collar crime, particularly when it exploits public health crises, carries serious consequences. Schena’s case serves as a warning to other Silicon Valley entrepreneurs: innovation can’t excuse outright fraud, and the feds are watching.

Beyond the financial penalties, Schena’s reputation is shattered. He went from being a purported visionary to a convicted felon, a cautionary tale whispered in the halls of venture capital firms. The case also highlights the vulnerabilities within the medical technology industry, where hype and inflated valuations can often overshadow genuine innovation. It’s a reminder that due diligence is critical, not just for investors, but for regulators tasked with protecting the public from predatory schemes.

The investigation continues, with authorities examining whether other individuals within Arrayit were complicit in the fraud. Prosecutors are determined to hold all responsible parties accountable, sending a clear message that exploiting public trust for personal gain will not be tolerated. This isn’t just about one man’s greed; it’s about safeguarding the integrity of the healthcare system and protecting investors from unscrupulous actors.

Source: U.S. Department of Justice